Amantadin İnfüzyonu Sonrası Nörolojik İyileşme

Öz

Amantadin, N-methyl-D-aspartate antagonist özelliği ile dopaminerjik etki gösteren bir ajandır. Dopaminerjik ajanlar; psikiyatrik hastalıkların tamamlayıcı, Parkinson Hastalığı ve bilinç bozuklukları tedavisinde ve influenza profilaksisinde başarıyla kullanılmaktadır. Bu olgu sunumunda nedeni tam olarak belirlenemeyen GKS 7 olan komadaki bir hastada izleminin 10. gününde amantadin infüzyonu başlandı. Amantadin infüzyonunun 2. gününden itibaren dramatik düzelme görülen hasta izleminin 21. günü GKS 15 olarak taburcu edildi. Amantadin tedavisi, koma hastalarında iyileşmeyi hızlandırdığı ve arttırdığı için standart tedaviye ilave olarak kullanılabilir.

Anahtar Kelimeler

• Dopaminerjik ajan, amantadin, bilinç bozukluğu

The Neurological Improvement of a Patient after Amantadine Infusion

Öz

Amantadine is a dopaminergic agent with possible N-methylD-aspartate antagonist effects. Dopaminergic agents have been succesfully used for many purposes, including prophylaxis for influenza, adjunctive therapy for psychiatric diseases, treatment for Parkinson Disease, and treatment for disorders of consciousness. In this case report, amantadine infusion was started in a patient whose unconciousness could not be identified for ten days. A dramatic recovery was detected on the second day following amantadine infusion. The patient was discharged on the twenty-first treatment day with a 15 GCS score. Conclusion: Amantadine may be added to the standard therapy in comatose patients as it accelerates neurological functional recovery

Anahtar Kelimeler

• Dopaminergic agents, amantadine, consciousness

Kaynakça

1. Meythaler JM, Brunner RC, Johnson A, Novack TA. Amantadine to imp- rove neurorecovery in traumatic brain injury-associated diffuse axonal injury: a pilot double-blind randomized trial. J Head Trauma Rehabil 2002; 17: 300-13. [CrossRef]
2. Wu ST, Garmel MG. Improved neurological function after amantadi- ne treatment in two patients with brain injury. J Emerg Med 2005; 28: 289-92. [CrossRef]
3. Saniova B, Drobny M, Kneslova L, Minarik M. The outcome of patients with severe head injuries treated with amantadine sulphate. J Neurol Trans 2004; 111: 511-4. [CrossRef]
4. Giacino JT, Whyte J, Bagiella E, Kalmar K, Childs N, Khademi A, et al. Pla- cebo-controlled trial of amantadine for severe traumatic brain injury. N Engl J Med 2012; 366: 819-26. [CrossRef]
5. Tenovuo O. Pharmacological enhancement of cognitive and behavioral defi- cits after traumatic brain injury. Curr Opin Neurol 2006; 19: 528-33. [CrossRef]
6. Neurobehavioral Guidelines Working Group, Warden DL, Gordon B, McAllister TW, Silver JM, Barth JT, et al. Guidelines for the pharmacolo- gic treatment of neurobehavioral sequelae of traumatic brain injury. J Neurotrauma 2006; 23: 1468-501. [CrossRef]
7. Napolitano E, Elovic EP, Qureshi AI. Pharmacological stimulant treat- ment of neurocognitive and functional deficits after traumatic and non-traumatic brain injury. Med Sci Monit 2005; 11: 212-20.
8. Kraus MF, Smith GS, Butters M, Donnell AJ, Dixon E, Yilong C, et al. Effects of the dopaminergic agent and NMDA receptor antagonist amantadi- ne on cognitive function, cerebral glucose metabolism and D2 recep- tor availability in chronic traumatic brain injury: a study using positron emission tomography (PET). Brain Injury 2005; 19: 471-9. [CrossRef] 162